SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

McDonald's Corp. engages in the operation and franchising of restaurants. The firm operates through the following segments: U.S., International Operated Markets, and International Developmental Licensed Markets and Corporate. The U.S. segment focuses its operations on the United States. The International Operated Markets segment consists of operations and the franchising of restaurants in Australia, Canada, France, Germany, Italy, the Netherlands, Russia, Spain, and the U.K. The International Developmental Licensed Markets and Corporate segment consists of developmental licensee and affiliate markets in the McDonald’s system. Its products include Big Mac, Quarter Pounder with Cheese, Filet-O-Fish, several chicken sandwiches, Chicken McNuggets, wraps, McDonald's Fries, salads, oatmeal, shakes, McFlurry desserts, sundaes, soft serve cones, pies, soft drinks, coffee, and McCafe beverages. The company was founded by Raymond Albert Kroc on April 15, 1955 and is headquartered in Chicago, IL.

McDonald`s Corp

McDonald's Corp

McDonald's is attracting significant attention as traders debate whether the stock represents a deep-value buying opportunity or a declining asset amid concerns over U.S. consumer spending, menu pricing, and intense competition. While many investors view the recent pullback as a historic entry point for a defensive blue-chip stock, others argue that long-term structural issues and shifting consumer preferences suggest further downside.

Sovereign frontier cloud for AI that builds  AI agents are starting to build and operate real software. Agentic organizations are starting to coordinate people, code, data, payments, and governance. Both need a cloud that is sovereign, tamperproof, and always on.  The Internet Computer is that cloud.  Built on more than USD 500 million in R&amp;D, ICP uses advanced blockchain technology and cryptography to run entire software systems end-to-end on the network: websites, apps, services, data, payments, and governance. Code and data are protected by the protocol, replicated across independent nodes, and cannot be silently changed by a cloud provider, backend operator, or attacker.  Cloud engines make this infrastructure sovereign. They let organizations run ICP-powered compute across chosen providers, locations, and jurisdictions while keeping the same tamperproof and always-on guarantees of the network.  This is the real demand ICP serves: sovereign frontier cloud for AI agents and agentic organizations. Agents can build and update software. Organizations can run rules, assets, and governance as verifiable systems. The result is software that stays online, keeps its data, and remains under the control of its owners.  Developers and AI agents can build on the Internet Computer with any AI assistant using the ICP skill library at skills.internetcomputer.org, or by creating apps through conversation with Caffeine AI.  Computation on ICP is paid for by converting $ICP into cycles. $ICP is also used for staking and governance through the Network Nervous System.

Internet Computer

Investors are largely divided on the asset, with many holding long-term conviction based on the network's decentralized cloud and AI infrastructure, while others remain frustrated by persistent price declines and token dilution concerns. The conversation is currently dominated by long-term holders debating the project's technological utility versus its historical market performance.

New Era Energy & Digital, Inc. is an exploration and production company, which engages in selling oil and natural gas products. The company was founded on February 6, 2023 and is headquartered in Midland, TX.

New Era Energy & Digital Inc.

The stock is attracting attention due to high short interest and market anticipation of a signed Power Purchase Agreement (PPA) and tenant deal for its Texas data center project. Traders are largely focused on a potential short squeeze, citing significant institutional accumulation and the belief that the company's off-grid energy strategy provides a unique advantage in the data center market.

Vertiv Holdings Co. engages in the design, manufacture, and service of critical digital infrastructure technology for data centers, communication networks, and commercial and industrial environments. The firm also offers power management products, switchgear and busbar products, thermal management products, integrated rack systems, modular solutions, and management systems for monitoring and controlling digital infrastructure. It operates through the following geographical segments: Americas, Asia Pacific, and Europe, Middle East, and Africa (EMEA). The Americas segment includes products and services sold for applications within the data center, communication networks and commercial and industrial markets in North America and Latin America. The Asia Pacific segment consists of products and services sold for applications within the data center, communication networks and commercial and industrial markets throughout Greater China, Asia, and India. The EMEA segment focuses on products and services sold for applications within the data center, communication networks, and commercial and industrial markets in Europe, Middle East, and Africa. The company was founded in 1946 and is headquartered in Westerville, OH.

Vertiv Holdings Co - Ordinary Shares - Class A

Vertiv Holdings Co

Vertiv is trending as the community highlights its role in the AI data center buildout, specifically regarding power delivery and thermal management solutions. Traders are expressing bullish sentiment, focusing on the company's strong guidance, backlog growth, and expansion in global manufacturing capacity to meet rising demand from hyperscalers.

Zcash is a privacy-focused cryptocurrency that uses trustless zero-knowledge proofs to enable fully encrypted transactions while maintaining blockchain transparency and security. It was the first cryptocurrency to implement zero-knowledge encryption for private peer-to-peer payments, addressing the fundamental privacy gap in traditional cryptocurrencies that expose transaction details publicly.   With a fixed supply of 21 million ZEC and a halving schedule similar to Bitcoin, Zcash allows users to prove transactions are valid without revealing sensitive information like wallet balances, transaction amounts, or participant identities, making it suitable for everyday payments, long-term savings, and cross-border money transfers where financial confidentiality matters.  The protocol operates on its own blockchain currently using Proof-of-Work consensus, though it's evolving toward Proof-of-Stake through the planned "Crosslink" upgrade to enhance security, scalability, and energy efficiency. Zcash employs trustless zero-knowledge proofs (Halo) within its Orchard shielded pool to verify transactions without revealing sender, receiver, or amount information.   Users can choose between transparent public transactions and shielded private transactions through Unified Addresses, which work with both types. The network is faster and cheaper than Bitcoin, with new blocks mined every 75 seconds and transaction fees typically just a fraction of a cent. Privacy adoption has surged in 2025, with over 30% of total ZEC supply now held in fully shielded pools.  Zcash was created by a group of scientists in 2013 who initially proposed Zerocoin as a privacy extension to Bitcoin before building a standalone protocol. The ecosystem operates with a self-funded development model where block rewards support independent teams through the Zcash Community Grants Committee and a new Coinholder-Controlled Fund.

Zcash

Zcash is experiencing a parabolic surge driven by strong buying momentum, a technical breakout above long-term resistance, and optimism surrounding the upcoming launch of its first spot ETF. While many traders are celebrating the price gains and comparing the asset to Bitcoin's early growth, others are warning of potential volatility and expressing skepticism regarding the sustainability of the move.

The Compound Governance Token is a governance token on the Compound Finance lending protocol, COMP allows the owner to delegate voting rights to the address of their choice; the owner’s wallet, another user, an application, or a DeFi expert. Anybody can participate in Compound governance by receiving delegation, without needing to own COMP.  Anybody with 1% of COMP delegated to their address can propose a governance action; these are simple or complex sets of actions, such as adding support for a new asset, changing an asset’s collateral factor, changing a market’s interest rate model, or changing any other parameter or variable of the protocol that the current administrator can modify.

Compound

Compound is trending as investors debate the asset's long-term potential, citing its low circulating supply and institutional pivot while some express frustration over persistent price stagnation compared to other DeFi tokens. Community members are divided, with some actively accumulating on dips while others criticize the lack of significant momentum and label the project's price action as stagnant.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix is seeing intense discussion regarding its commercial rollout and upcoming earnings, with traders debating the potential for a short squeeze against a backdrop of high institutional ownership and conflicting sentiment over institutional positioning. While some investors emphasize the long-term value of DefenCath and anticipation for Rezzayo, others are focused on volatility and potential downside risks leading into the reporting date.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energy is trending after being selected for inclusion in the S&P 500, a development that triggered significant bullish sentiment and after-hours price appreciation as traders anticipate mechanical buying pressure from index-tracking funds. The conversation is further fueled by community interest in the company's role in powering AI data centers and ongoing retail speculation surrounding recent political stock disclosures.

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010 and is headquartered in Novato, CA.

Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc

The stock is receiving attention following a significant decline after the failure of its Phase 3 Aspire trial for an Angelman syndrome treatment, which missed both primary and secondary endpoints. While some investors view the sell-off as a severe overreaction and a buying opportunity due to the company's remaining commercial portfolio and upcoming catalysts, others express concern over the pipeline setback and the resulting shift in focus toward commercial execution and cost-cutting.

Groupon, Inc. engages in the global scaled two-sided marketplace that connects consumers to merchants. It operates through the North America and International geographical segments. The company was founded by Andrew D. Mason, Eric Paul Lefkofsky, and Bradley A. Keywell in October 2008 and is headquartered in Chicago, IL.

Groupon Inc

Elevated reported short interest, a perceived tight float, buybacks and call-heavy options positioning are driving a dominant short- and gamma-squeeze thesis around Groupon. Bullish traders view the AI-led turnaround and earnings outlook as potential catalysts, while skeptics argue the squeeze depends on fresh volume and question whether the underlying business and short-interest data justify the optimism.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Spero Therapeutics (SPRO) Q2 2026 Earnings Call Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

Spero Therapeutics Names Debra Jeske Zack As Chief Medical Officer

(RTTNews) - Spero Therapeutics, Inc. (SPRO), a clinical-stage biopharmaceutical company, on Monday said it has appointed Debra Jeske Zack as Chief Medical Officer...

Innovent Biologics and Spero Therapeutics Announce Exclusive License for IBI355 (SP001), a Phase 2-Ready Third-Generation Anti-CD40L Antibody

Innovent Biologics and Spero Therapeutics Announce Exclusive License for IBI355 (SP001), a Phase 2-Ready Third-Generation Anti-CD40L Antibody Innovent Biologics and Spero Therapeutics Announce Exclusive License for IBI355 (SP001), a Phase 2-Ready Third-Generation Anti-CD40L Antibody PR Newswire SAN...

Brains, AI Imaging, and Breakthrough Antibiotics Ignite Investor Buzz

The healthcare and biotechnology sector continues to generate a steady stream of meaningful catalysts as companies advance novel therapies, secure regulatory milestones, strengthen intellectual property portfolios, and expand commercialization efforts. Recent developments from CervoMed (NASDAQ:CRVO), Butterfly Network (NYSE:BFLY), NeOnc (NASDAQ:NTHI), Spero Therapeutics (NASDAQ:SPRO), GSK (NYSE:GSK), and IceCure Medical (NASDAQ:ICCM) highlight several emerging themes shaping the sector, including neurodegenerative disease treatment, AI-powered diagnostics, antimicrobial resistance, minimally invasive cancer care, and synthetic biology.

GSK's Utebzi Wins FDA Nod for Complicated Urinary Tract Infections

GSK wins FDA approval for Utebzi, the first oral carbapenem for complicated UTIs, further expanding its anti-infectives portfolio.

Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)

GSK plc (LSE/NYSE: GSK) and Spero Therapeutics (Nasdaq: SPRO) today announced that the US Food and Drug Administration (FDA) has approved Utebzi, an oral antibiotic for the treatment of complicated urinary tract infections (cUTIs) including pyelonephritisi, caused by certain susceptible pathogensii...

Compass Pathways Elects Kathleen Tregoning to Board of Directors

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the election of Kathleen Tregoning to its Board of Directors at the annual general meeting of shareholders. Ms. Tregoning is expected...

Spero Therapeutics, Inc. (NASDAQ:SPRO) Sees Significant Growth in Short Interest

Spero Therapeutics, Inc. (NASDAQ:SPRO - Get Free Report) was the target of a large growth in short interest during the month of April. As of April 15th, there was short interest totaling 737,720...

GSK Q1 Earnings Beat Estimates, Specialty Medicines Drive Sales Growth

GSK Q1 earnings and revenues beat estimates as Specialty Medicines lifted sales, with HIV, oncology and respiratory growth. The guidance for 2026 remains unchanged.

Spero Therapeutics (NASDAQ:SPRO) Share Price Passes Above 50 Day Moving Average   - What's Next?

Spero Therapeutics (NASDAQ:SPRO) Shares Pass Above 50-Day Moving Average - Here's What Happened...

Reported GAAP EPS of -$0.16 down -433.33% YoY

Spero Therapeutics faces significant financial risks, including a history of losses, dependence on the successful development of SP001, and reliance on GSK for future royalty revenues from Utebzi.

Spero Therapeutics achieved FDA approval for Utebzi, in-licensed a new lead program SP001, and secured a $105.0 million royalty financing transaction to support operations through the second half of 2029.

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on identifying, developing, and commercializing treatments involving bacterial infections, including multi-drug resistant bacterial infections, and rare diseases Its pipeline product candidates include Tebipenem HBr, SPR720, and SPR206. The company was founded by Ankit A. Mahadevia and Laurence Rahme in April 2013 and is headquartered in Cambridge, MA.

Spero Therapeutics Inc

GSK, Spero Therapeutics Stop Antibiotic Trial For Complicated Urinary Tract Infections Early After Positive Results, Retail’s Thrilled

Equity

Neutral Sentiment

The Federal Reserve hasn't raised rates at all in 2026, but hawkish comments from Fed Chair Kevin Warsh at the Jackson Hole symposium have pushed September rate hike odds as high as 66%, a sharp jump from under 40% just a week earlier. How many rate hikes do you expect from the Fed in 2026? Vote and explain your reasoning in the comments.

How many rate hikes do you expect from the Fed in 2026?

Current Price	$1.21
Prev Close	$1.22
Open	$1.20
Dividend Yield	0.00%
50-Day Moving Average	$1.47
Beta	0.95
Avg. Volume	580,609.83
PE Ratio	11.08

52-Week High	$3.08
52-Week Low	$1.08
Market Capitalization	$71.05M
EPS (Annual)	$0.1452
Price to Book	1.59
Revenue Per Employee	$2.38M

Feed

News

Sentiment

Earnings

Fundamentals

Info

SPRO Fundamentals